About Us

Prescient is a product strategy and decision support consultancy that helps clients make better clinical and commercial decisions, resulting in enhanced outcomes for patients, customers and shareholders. Founded in London in 2007, Prescient has since expanded its global reach through offices in New York, San Francisco, New Delhi and Beijing. Prescient partners with most of the leading multinational pharmaceutical companies, as well as a growing number of emerging biotech organizations.

Our work is truly global, with about 65% of our engagements being focused on the mature markets of North America, Europe and Japan, and the remaining 35% helping clients realize opportunities in the emerging markets of APAC, LATAM and EMEA. Besides supporting innovative products in oncology, immunology, cardiology, neurosciences and infectious diseases, we are heavily involved in biosimilars, generics, vaccines and rare diseases.

Prescient Overview

Partnering With Us

Our engagements are designed to answer three fundamental questions asked by clients:

  • How will the market and competition look at a specific time in the future, and what must we demonstrate to succeed?
  • How can we develop a clinical and commercial value proposition that resonates with future market needs and stands out from the competition?
  • Which customers will determine the success of our brand and how can we communicate our value to them?

Our relationships with assets, brands or franchises typically last for more than 5 years. We often start a partnership with a product team in early Phase II and provide constant support through launch and beyond.

Our success is built on employing the best people and developing a culture where we can guarantee our clients quality, flexibility and humility.

Over the past decade, we have seen our clients’ businesses evolve from a predominantly primary care model to more targeted, patient-centric specialty businesses. Prescient has joined them on this journey, building an integrated team of more than 100 functional, therapeutic and methodology experts.

Why the Bee?
Bees use intelligence, observation, collaboration, communication and hard work to develop solutions to challenges.

Functons with which Prescient partners with the clients.

Meet Our Leadership

Dr. Nick Edwards


Nick serves as the Chairman of Prescient’s Board of Directors. He holds a degree in physiological sciences from The Queen’s College, University of Oxford, and completed his training in clinical medicine (BM, BCh) at Green College (now Green Templeton College), University of Oxford. Nick practiced in the areas of cardiology and general surgery before joining Andersen Consulting (now known as Accenture), eventually becoming the global leader of Accenture’s pharmaceutical R&D business during his 18-year tenure. In 2005, he founded Kinapse to provide consulting and outsourcing services to the pharmaceutical industry. Nick served as Kinapse’s Chairman until the company was sold to HgCapital in early 2016.

Jamie Denison-Pender

Chief Executive Officer

Jamie is our CEO and a career consultant, having spent more than 20 years growing and managing healthcare-focused consultancies. In 2007, he became managing director of a global competitive strategy consultancy and led the company’s transition from an industry generalist to a biopharmaceutical specialist. He rebranded the company to Prescient in 2010 and led a management buyout in 2014. Jamie remains actively involved with our clients, mainly focusing on strategic simulation workshops and mature brand strategies.

Dr. Rakesh Verma

President, EMEA and APAC

Rakesh is the President of our EMEA and APAC businesses. After earning a degree in veterinary medicine, he completed his Master’s and doctoral degrees in immunology at Imperial College, School of Medicine, London. He was then recruited by oncology biotech firm Antisoma, which specialized in the development and out-licensing of monoclonal antibodies. He joined Prescient in 2007. His renowned expertise in the development and commercialization of biologics makes him an extremely valuable asset to our oncology, immunology and biosimilar clients.

Dr. Paul Harney

President, North America

Paul oversees our business activities in North America. Since completing his PhD in chemistry at Stony Brook University, he has spent more than 20 years providing guidance and support to the healthcare industry. He has held leadership roles at various consulting firms that engage with biopharmaceutical and medical technology companies in nearly all functional areas, including sales, marketing, medical affairs, business development and supply chain. Paul’s focus at Prescient is helping our clients achieve and sustain peak commercialization targets across a wide range of therapy areas.


Swati Kkatyal

Vice President, Head of Indian Operations

Swati manages our New Delhi office and is responsible for Prescient’s APAC business. Swati has an MSc in biotechnology and pharmacology, and an MBA from the University of Sheffield. After joining us in London in 2008, she moved to India in 2010 to open our New Delhi office, which she has built into a critical part of our business. During her time with Prescient, she has consulted across a wide range of therapy areas and been actively involved in client engagements. In the past four years, she has specialized in mature brand planning and launching specialty products in the APAC region.

Victoria Muir

Vice President, Chief Talent Officer

Victoria is our Vice President and Chief Talent Officer. She has a Bachelor’s degree (Hons) in economics from Nottingham Trent University, as well as several accounting and human resources certifications. Victoria spent more than 20 years in senior leadership positions at KPMG across Europe and Asia, where she developed extensive experience and a proven ability to implement change in complex and cross-cultural environments. At Prescient, her role involves working with senior stakeholders to effectively prioritize and execute the people activities needed to achieve defined strategic objectives.

Dr. Debasish Talukdar

Vice President, Head of Advisory

Debasish is our Vice President, Global Head of Advisory and Chief Client Officer. He started his career as a licensed medical practitioner and holds an MBA from the Indian Institute of Management Calcutta. After a brief stint at P&G, he made the move to strategy consulting, and then spent ten years at Bain & Company, where he was a leader in the healthcare practice. Debasish has extensive international experience advising biopharma clients on value creation through corporate, business unit, disease area and product-focused strategies.

Nick Denison-Pender

Chief Operating Officer, Global

Nick, our COO, joined Prescient in 2010. After studying engineering, he held various positions focused on business improvement, mainly in the construction industry. He has worked in many parts of the world, establishing and embedding businesses into local markets. At Prescient, he holds overall responsibility for our operations and infrastructure and has been instrumental in setting up the departments, processes and procedures required to support a growing business.

Sidnee Pinho

Chief Operating Officer, North America and Advisory

Sidnee is the Chief Operating Officer of North America and Advisory. She earned her MBA from New York University’s Stern School of Business and has spent more than 20 years helping life sciences strategy firms evolve their operating discipline, talent deployment and business model to support aggressive growth. At Prescient, Sidnee is responsible for driving operational and organizational initiatives that support the company’s strategic objectives.

Andrew McMeeking

Chief Financial Officer

Andrew joined our team in 2012 after holding finance director positions in marketing services companies such as Publicis and Gyro. He is a qualified chartered accountant and holds an honors degree in accountancy from Dundee University. He manages Prescient’s finances and is the company secretary. He was heavily involved in setting up the shared resources service center in the UK and arranging Prescient’s de-merger/MBO in 2014.

Andrew Ferguson

Baird Capital Investor

Andrew, one of our non-executive board members, has close to 25 years’ experience in the private equity industry. He started his professional career at Price Waterhouse in 1986, where he qualified as a chartered accountant before moving into a corporate finance role. He joined North of England Ventures in 1993 to manage a regional investment fund before moving to Granville, subsequently Baird Capital Partners, in 1996. At Baird, he is responsible for investment activities in the UK with a particular focus on the business services and healthcare sectors and has held directorships in a large range of companies across these sectors.

Michael Holgate

Baird Capital Investor

Michael sits on our board of directors. He holds Bachelor’s and Master’s degrees in chemistry from the University of Bristol, where he graduated with First Class Honours. Michael began his career as a chemist working at GlaxoSmithKline and Synairgen. He then joined PricewaterhouseCoopers in its Transaction Services Team before spending time in Investment Banking at Spectrum Corporate Finance. Michael joined Baird Capital in 2014 and has a particular focus on technology and service-based businesses. During his time at Baird, Michael has spent time working in both London and Chicago. Michael is a chartered accountant.

Nader Naeymi-Rad


Nader serves on Prescient’s Board as a Non-Executive Director. He has a BA from Georgetown University. He was previously the Chief Executive Officer of Campbell Alliance, where he oversaw all of the firm’s business units to ensure its continued growth, commitment to client service, development of new service lines and geographic expansion. Nader is an expert in developing and implementing business strategy, process improvement and business development solutions for clients in the pharmaceutical and biotechnology industries.

Harminder S. Bhatia

Associate Vice President

Harminder is an Associate Vice President and has been delivering high-impact projects to our clients since 2010. He has an MS degree in chemistry from Virginia Commonwealth University and a BPharm degree from Panjab University. He is also a registered pharmacist. Before joining Prescient, he worked in pharmaceutical product manufacturing, regulatory and corporate departments. At Prescient, Harminder has focused on analyzing competitors and market scenarios for biosimilar, generic and novel products. Additionally, he has worked at building client relationships and motivating teams to better serve client needs.

Dr. Raymond Donninger

Vice President, Head of Insights & Analytics

Raymond is our Vice President, Head of Global Analytics. He completed degrees in medical biochemistry and medicine from the University of Cape Town, South Africa, and has an MBA from the Gordon Institute of Business Science, South Africa. Raymond worked as a hospital doctor for two years in the accident and emergency field, and as a general practitioner for an additional 7 years. Since then, he has acquired more than 20 years’ experience working in biopharmaceutical research and development in academia, the biotech sector and the CRO industry. At Prescient, Raymond is responsible for managing a complex set of relationships between Prescient’s software development team, Global Analytics Center, consultancy teams and clients.

Ben Doran

Vice President

Ben is an Vice President and supports both our East and West Coast clients in the US. He holds a BSc in biomedical sciences and an MSc in biomedical engineering, and gained eight years’ experience in biotech prior to joining Prescient in 2010. Ben has held progressively more senior roles at Prescient, which has given him a deep understanding of what is needed to build and motivate teams that deliver results with a high degree of client satisfaction. Ben has also been closely involved in managing projects across multiple therapeutic areas, including oncology, immunology and biosimilars.

Dr. Mark Little

Senior Vice President

Mark is the Senior Vice President of our North American business. After completing a PhD in biochemistry at The Ohio State University, he spent more than 10 years running GSK’s competitive strategy function and 10 years as a key member of Covance’s executive strategy team. Mark engaged with Prescient throughout his tenure with GSK and Covance before joining us in 2013. He is responsible for establishing, solidifying and expanding client relationships by engaging with industry executives and bringing clarity to our solutions.

Dr. Aviral Maheshwari

Vice President

Aviral is an Vice President at Prescient. He completed his MBBS and MS degrees at Jawaharlal Nehru Medical College, India, and his MBA at IESE Business School, Spain. Aviral has developed a strategic understanding of both the clinical and commercial sides of the life sciences industry from working as a physician for eight years and holding strategic consultancy roles at GlaxoSmithKline Biologicals and Grail Research. Since joining Prescient in 2010, Aviral has examined all aspects of the product life cycle for companies developing biologics, biosimilars and generics, OTC medicines, vaccines and medical devices within CVMD, respiratory disease, gastroenterology, immunology, dermatology, neurology and ophthalmology.

Tarun Ojha

Vice President, Head of Software Development

Tarun is spearheading the development of our Decision Support Software (DSS). He obtained his Master’s degree in computer applications from M.B.M Engineering College, Jodhpur, India, and has more than 18 years of experience in product management, enterprise application design and development, and entrepreneurship. He has worked with small- to medium-sized technology start-ups and is an expert in product ideation, conceptualization, development from POC to final product, and market releases. At Prescient, Tarun’s role involves leading and delivering a software platform that creates value for our clients and drives efficiencies within our project teams.

Dr. Elisavet Primpidou

Vice President

Elisavet joined Prescient in 2008 and heads up our business development activities in Europe. She holds a PhD in molecular immunology and an MSc in medical genetics from Brunel University London, as well as a BSc in biology from the Royal Holloway University of London. As a consultant to the pharmaceutical industry, Elisavet has gained extensive experience in various aspects of drug development and commercialization, strategic marketing and life cycle management, providing critical analysis and recommendations to brand teams supporting new and existing products in oncology, malignant and non-malignant hematology, vaccines, rare diseases and other areas. Elisavet uses her expertise in evidence gathering to identify key unmet needs, gaps in strategy, opportunities for differentiation and potential threats.

Dr. Anthony Starling

Vice President

Anthony is one of the longest-serving members of our team, having joined in 2002. He earned his PhD in pharmacology before becoming a postdoctoral researcher at the University of Southampton. From there, he joined the world of healthcare market research, working for the likes of MMR International, IMS Health and NOP World (now GfK). He has consulted across the therapeutic spectrum and throughout the product life cycle but particularly enjoys developing clinical strategies within oncology, infectious disease and cardio-metabolic diseases.

Amrit Bawa

Amrit has been with Prescient since 2011 and specializes in oncology and hematology. He holds a master’s degree in biotechnology from the University of Pennsylvania. He has directed several projects in Europe and the US. His versatile experience in multiple engagement types and expertise enables him to deliver exceptional services to Prescient’s clients.

Courtney Carlson

Courtney, our Associate Director of QC and Compliance, joined Prescient in 2012. After earning a master’s degree in Spanish translation, she pursued a job opportunity in Bogotá, Colombia, where she translated medical, legal and technical texts and designed an assessment program to monitor the quality of her fellow translators’ work. Courtney now uses her attention to detail to oversee Prescient’s experienced QC Team, which is responsible for editing all of our deliverables, and to ensure that Prescient has the necessary resources in place to fulfill our legal and contractual obligations.

Nadia Gonzalez

Nadia joined the Prescient team as the US Financial Controller and HR Director. After earning her accounting degree, she developed financial expertise through working with high-end retail and luxury brands headquartered in New York City. While working in retail, Nadia was responsible for the financial reporting and oversight of nationally recognized brands with a presence across the country. The technical expertise and business acumen that she has acquired over the past 15 years have proven to be an invaluable asset to our organization.

Dr. Connie Kim

Connie is one of our Principals and has led numerous key projects since joining Prescient in 2014. She holds a PhD in cell biology from Columbia University. Connie previously worked in South Korea as a lead analyst for the healthcare business sector at LG Corp and as a scientific reviewer for drug development projects at a government agency. Connie specializes in biosimilars, immunology and oncology.

Evguenia (Jane) Klimenko

Jane joined the Prescient team as a Principal in 2018. She holds a PhD in molecular and cell biology from UC Berkeley and a Bachelor’s degree in biochemistry from the University of Florida. Before Prescient, she worked for more than six years in strategic consulting for pharma and biotech clients. Her functional expertise is in product strategy and supporting market analytics, and her experience covers several therapeutic areas, including specialty and primary care, with notable experience in rare disease. At Prescient, Jane is focused on building out our Advisory service line on the West Coast.

Christina Maffei

Christina joined Prescient as our Principal, Global Marketing, and heads up all marketing and communications functions. After earning a master’s degree in pharmaceutical business, she pursued careers in both non-profit and commercial sectors. Her experience includes leading marketing strategy for global oncology teams, as well as regionally for the Americas and in emerging markets. Christina is responsible for elevating the positioning and messaging of the Prescient brand through the development of strategic marketing programs and thought leadership initiatives.

Dr. Wilfredo Ortiz

Wilfredo has been a trusted member of our team since 2009. He has a PhD from the University of Florida in computational chemistry with a focus on molecular simulations of polymers and biomolecules. He also completed a two-year postdoctoral fellowship at the University of Houston as part of the NIH Nanobiology Training Program, performing theoretical research on DNA microarrays. During his doctoral studies, he won awards for excellence in teaching, graduate research and scientific publication. Since joining Prescient, Wilfredo has specialized in vaccines, cardiology and metabolic diseases, respiratory disease and biosimilars.

Dr. Kallal Pramanik

Kallal is one of the longest-serving members of our India-based team. He has master’s and doctoral degrees in biotechnology, as well as a master’s degree in business administration. After holding various academic research posts in oncology, Kallal became a Lead Scientist at Connexios Life Sciences, where the focus of his group was to design in vitro and ex vivo assays reflecting human pathologies in type 2 diabetes mellitus and to test the efficacy of in-house drugs. Since joining Prescient in 2010, Kallal has managed new product and mature product brand planning projects in the areas of neurology, oncology, immunology and diabetes in both regulated and semi-regulated markets.

Dr. Fancy Sarswat

Fancy joined Prescient in 2010 and is one of our Principals. She received her Bachelor’s degree in pharmaceutical sciences from Goa College of Pharmacy, India, and her PhD in pharmaceutical sciences from Texas Tech University Health Sciences Center, Amarillo, Texas. She worked as an assistant professor in the College of Pharmacy at Lipscomb University, Nashville, Tennessee, where she taught the biopharmaceutics, pharmacokinetics and pharmaceutics courses and published research in highly distinguished international peer-reviewed journals. Besides her experience in academia, Fancy has worked at Abbott Laboratories Limited and Ranbaxy Laboratories in both the production and the quality control departments. At Prescient, Fancy has managed respiratory and vaccine projects and worked extensively in the neuroscience space, especially on neurodegenerative and neurodevelopmental disorders. Furthermore, Fancy has extensive experience supporting pharma clients both defending from biosimilars and developing biosimilars of their own.

Dr. Nick Turner

Nick, one of our Senior Principals, has a PhD in pharmacology from the University of London and conducted postdoctoral research at London’s Royal Postgraduate Medical School. He began his career in the pharmaceutical industry as a senior scientist to lead the pharmacology effort on discovery research projects in airway diseases at Rhône-Poulenc (now Sanofi) and in asthma and type 2 diabetes at SmithKline Beecham (now GSK). He then spent nearly 19 years as a senior equity analyst at Mirabaud Securities and Jefferies, with responsibility for the pharmaceutical and biotechnology industries. At Prescient, Nick is overseeing some of our projects in oncology.